Bruce D. Jackson
Stock Analyst at Benchmark
(1.98)
# 2,866
Out of 5,127 analysts
10
Total ratings
44.44%
Success rate
7.33%
Average return
Main Sectors:
Stocks Rated by Bruce D. Jackson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HUMA Humacyte | Maintains: Buy | $11 → $10 | $1.05 | +852.38% | 2 | Jan 21, 2026 | |
| EXAS Exact Sciences | Downgrades: Hold | n/a | $103.35 | - | 2 | Nov 24, 2025 | |
| MLSS Milestone Scientific | Maintains: Speculative Buy | $1.25 → $1 | $0.26 | +289.11% | 1 | Nov 20, 2025 | |
| BLTE Belite Bio | Maintains: Buy | $80 → $132 | $176.91 | -25.39% | 1 | Oct 31, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Speculative Buy | $14 → $7 | $0.26 | +2,545.50% | 1 | Sep 15, 2025 | |
| UNCY Unicycive Therapeutics | Maintains: Speculative Buy | $3 → $21 | $6.37 | +229.67% | 1 | Sep 15, 2025 | |
| HBIO Harvard Bioscience | Maintains: Speculative Buy | $3 → $2 | $0.60 | +232.78% | 1 | Sep 10, 2025 | |
| CLNN Clene | Maintains: Buy | $33 → $31 | $4.42 | +601.36% | 1 | Sep 10, 2025 |
Humacyte
Jan 21, 2026
Maintains: Buy
Price Target: $11 → $10
Current: $1.05
Upside: +852.38%
Exact Sciences
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $103.35
Upside: -
Milestone Scientific
Nov 20, 2025
Maintains: Speculative Buy
Price Target: $1.25 → $1
Current: $0.26
Upside: +289.11%
Belite Bio
Oct 31, 2025
Maintains: Buy
Price Target: $80 → $132
Current: $176.91
Upside: -25.39%
Reviva Pharmaceuticals Holdings
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $14 → $7
Current: $0.26
Upside: +2,545.50%
Unicycive Therapeutics
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $3 → $21
Current: $6.37
Upside: +229.67%
Harvard Bioscience
Sep 10, 2025
Maintains: Speculative Buy
Price Target: $3 → $2
Current: $0.60
Upside: +232.78%
Clene
Sep 10, 2025
Maintains: Buy
Price Target: $33 → $31
Current: $4.42
Upside: +601.36%